Company
Headquarters: Cravinhos, SP, Brazil
Employees: 17,952
CEO: Mr. Kleber Cesar Silveira Gomes
R$1.00 Billion
BRL as of July 1, 2024
US$177.0 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, operates in the animal health industry primarily in Brazil. The company operates through Production Animals, Companion Animals, and International Operations segments. It manufactures and trades in medicines, including anti-inflammatories, antibiotics, anticoccidials, antimastitics, ectoparasiticides, endectocides, endoparasiticides, hemoparasiticides, inoculants, therapeutics, products for animal reproduction, and vaccines; and other veterinary products for cattle, swine, poultry, sheep, horses, and goats. The company also manufactures veterinary solutions for dogs and cats, such as anesthetics, sedatives, anti-inflammatory, antibiotic, antimicrobial, dermatological, ectoparasiticide, endoparasiticide, dermocosmetic, and otological products. In addition, it offers vaccines and other veterinary products for production and companion animals. The company was formerly known as A.H.N.S.P.E. Empreendimentos e Participações S.A. Ouro Fino Saúde Animal Participações S.A. was incorporated in 1987 and is headquartered in Cravinhos, Brazil.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Ouro Fino Saude Animal Participacoes SA has the following listings and related stock indices.
Stock: Bovespa: OFSA3 wb_incandescent